United Therapeutics (UTHR) Cash & Current Investments (2009 - 2026)

United Therapeutics has disclosed Cash & Current Investments across 18 years of filings, most recently posting $2.2 billion for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $2.2 billion, down 35.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 billion (down 35.15% YoY), and the FY2025 annual result was $2.9 billion, down 10.61% from the prior year.
• Cash & Current Investments came in at $2.2 billion for Q1 2026 at United Therapeutics, down from $2.9 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $3.3 billion in Q3 2024 to a low of $2.2 billion in Q1 2026.
• The 5-year median for Cash & Current Investments is $2.9 billion (2023), against an average of $2.8 billion.
• Across the five-year window, Cash & Current Investments soared 47.03% in 2022 and sank 35.15% in 2026, its largest moves.
• United Therapeutics' Cash & Current Investments stood at $2.8 billion in 2022, then increased by 5.47% to $3.0 billion in 2023, then climbed by 9.11% to $3.3 billion in 2024, then retreated by 10.61% to $2.9 billion in 2025, then dropped by 26.25% to $2.2 billion in 2026.
• The last three Cash & Current Investments figures came in at $2.2 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.